CAMILLA trial — Cabo + Durva for metastatic refractory MSS CRC: Dr. Saeed
In this DocTalk organized by Paltown Scientific Director Dr. Manju George, Dr. Anwaar Saeed from Kansas University Cancer Center talks about the CAMILLA trial for treatment-refractory Microsatellite Stable (MSS) stage IV colorectal cancer.
Recorded in May, 2022.
Table of contents
00:00: Introduction
01:35: Dr. Saeed outlines her research activities at KU Cancer center
06:26: Background/rationale for CAMILLA trial, Cabo & Pembro each as single agents in CRC
10:47: Mechanism of action of Cabozantinib
14:10: Cabo as a “dirty Tyrosine Kinase Inhibitor (TKI)”
15:14: Cabo + Immunotherapy for CRC
17:28: CAMILLA trial introduction — Dose-limiting toxicity evaluation
21:05: Results of the Phase 1b study
25:30: PD-L1 CPS & its role in treatment response
26:30: Phase II multi-cohort schema
28:31: Phase II Cabo + Durva in MSS mCRC results
28:50: Background
30:45: Methods
33:14: Baseline characteristics of the patient population
35:32: Safety data from the study
38:48: Efficacy data
51:14: Conclusions
51:49: Other VEGF TKI + IO combinations
53:00: Coming soon! STELLAR 303 600 patient global Phase 3 trial using offspring of Cabo + Atezo vs Rego in MSS stage IV CRC with RAS WT tumors